EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β

Carla Moran iD, Julie Martin-Grace iD, Greta Lyons, Laura Watson iD, Kevin Taylor, Susan Oddy, David Halsall, Krishna Chatterjee iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Carla Moran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Section, Beacon Hospital, Dublin D18 AK68, Ireland. Hauptthemen laut MEDLINE: Triiodothyronine, Thyroxine, Hyperthyroidism, Thyroid Hormone Resistance Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Department of Health, NIHR Cambridge Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The treatment of resistance to thyroid hormone β (RTHβ) is challenging because features of hyperthyroidism in some tissues coexist with a hormone-resistant, hypothyroid state in other organs.

Objective

To determine whether triiodothyroacetic acid (TRIAC) therapy alleviates hyperthyroid symptoms and changes circulating thyroid hormones, resting energy expenditure and metabolic parameters in RTHβ.

Design

Retrospective cohort study.

Setting

Referral center.

Participants

Eight adult patients with RTHβ (mean age 41 years; 4 males, 4 females). Main Outcome Measures Hyperthyroid Symptom Scale (HSS) score, serum free T4 and total T3, resting energy expenditure, sleeping heart rate, fasting lipids, and glucose and systemic insulin resistance.

Results

From abnormally elevated levels prior to treatment, TRIAC therapy lowered HSS scores (baseline 17.5 vs posttreatment 6; P = .0014), showed a reduced resting energy expenditure trend (baseline Z-score +1.3 vs posttreatment +0.89; P = .38) and normalized circulating free T4 (baseline free T4 30 pmol/L vs posttreatment 17 pmol/L; P = .007) and total T3 (baseline 2.5 nmol/L vs posttreatment 1.4 nmol/L; P = .001) concentrations in 7 out of 8 patients, without any rise in their serum TSH (baseline 2.1 mU/L vs posttreatment 1.7 mU/L; P = .65), total cholesterol (baseline 4.9 mmol/L vs posttreatment 4.8 mmol/L; P = .81), and triglyceride (baseline 1.3 mmol/L vs post-treatment 1.3 mmol/L; P = .44). Their mean sleeping heart rate (baseline 60 bpm vs posttreatment 58 bpm; P = .56) and plasma N-terminal pro-brain natriuretic peptide (baseline 55 ng/L vs posttreatment 54 ng/L) were unchanged. TRIAC treatment was well tolerated, with no side effects.

Conclusion

TRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriiodothyronineThyroxineHyperthyroidismThyroid Hormone Resistance SyndromeHumansMaleFemaleAdultRetrospective StudiesMiddle AgedEnergy MetabolismTreatment OutcomeInsulin ResistanceBasal Metabolism

Stichwörter der Autor:innen

resistance to thyroid hormone betathyroid hormone analoguetriiodothyroacetic acid (TRIAC)

Substanzen

TriiodothyronineThyroxine3,3',5-triiodothyroacetic acid

Autor:innen und Institutionen

  • Endocrinology Section, Beacon Hospital, Dublin D18 AK68, Ireland.
  • Endocrinology Department, St. Vincent's University Hospital, Dublin D04 T6F4, Ireland.
  • School of Medicine, University College, Dublin D04 V1W8, Ireland.
  • Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.
  • Metabolic Research Area, NIHR Cambridge Clinical Research Facility, Cambridge CB2 0QQ, UK.
  • Department of Blood Sciences, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.

ORCID-Profile: Carla Moran, Julie Martin-Grace, Laura Watson, Krishna Chatterjee

Förderung

  • Wellcome Trust
  • Department of Health
  • NIHR Cambridge Biomedical Research Centre
  • Medical Research Council Funding

Zitieren

APA

Moran, C., Martin-Grace, J., Lyons, G., Watson, L., Taylor, K., Oddy, S., Halsall, D., & Chatterjee, K. (2026). TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf583

Vancouver

Moran C, Martin-Grace J, Lyons G, Watson L, Taylor K, Oddy S, et al. TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf583

BibTeX
@article{Moran2026,
  author = {Moran, Carla and Martin-Grace, Julie and Lyons, Greta and Watson, Laura and Taylor, Kevin and Oddy, Susan and Halsall, David and Chatterjee, Krishna},
  title = {TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf583}
}
Kostenlos starten →